Jack Scannell is an accomplished drug development expert and founder of JW Scannell Analytics. With a wide-ranging background spanning across academia, management consulting, and the pharmaceutical industry, Scannell has amassed a wealth of knowledge and skills that are focused on solving some of the industry's most pressing challenges. His aim to improve "predictive validity" in drug R&D has led him to collaborate with several prominent research organizations and universities, including the University of Edinburgh, where he previously held an honorary fellowship.

Before founding his own company, Scannell worked as co-head of Pharmaceuticals - Equity Research at UBS and head of Discovery Research at e-Therapeutics PLC. He has also held several academic research roles, including university lecturer at the Neural Systems group at Newcastle University and researcher in Computational Neuroscience and Systems Neuroscience at the University of Oxford.

With a clear focus on evidential research, Scannell's work emphasizes the importance of improving the early-stage drug development process's predictability, fostering sustainable and successful drug discovery.